

REMARKS

I. Amendment

Claims 1-32 are cancelled.

Claim 33 is amended to clarify the claimed subject matter. Basis for claim 1, directed to a method of preparing a liposomal composition is found in original claim 33 and in Examples 1 and 2.

Claims 34, 36 and 37 are amended for consistency with claim 33.

Claim 39 is amended for technical clarity.


New claim 57 is directed to the embodiment where doxorubicin is the entrapped therapeutic agents. Support is found on page 17, line 2.

New claim 58 is directed to the embodiment where the targeting conjugate is a vesicle-forming lipid-polyethylene glycol-ligand conjugate, as described, for example, on page 21, lines 23-26 and page 24, lines 1-3.

Accordingly, no new matter has been added by these amendments.

The Examiner is invited to contact Applicants' representative at 650-838-4402 as needed to further prosecution of this application.

Respectfully submitted,



Judy M. Mohr
Registration No. 38,563

Date: April 7, 2004

CORRESPONDENCE ADDRESS

Customer No. 22918
(650) 838-4300